Hung Trinh’s Post

📣 Sanofi & Novavax entered an agreement resulting in 120% increase of stock shares value of Novavax 📈, what elevated Mabion S.A. valuation on Warsaw Stock Exchange (GPW) ❗️ This agreement includes: 1️⃣ a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan and South Korea where Novavax has existing partnership agreements); 2️⃣ a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines while Novavax retains the right to and is developing its own COVID-19-Influenza Combination vaccine candidate; 3️⃣ a non-exclusive license to use Novavax's adjuvanted COVID-19 vaccine for use in combination with non-flu vaccines; 4️⃣ a non-exclusive license to use the Matrix-M adjuvant in vaccine products. Mabion S.A. and Novavax have contract for antigen production that is finishing this year. Join board members presenting quarterly report on 14/05 (link below 👇) #biotech #nasdaq #gpw #vaccine #novavax #sanofi More info: https://lnkd.in/dTW5zzas

🌐 Ensuring Quality Standards for mRNA-LNP Vaccines: Exciting news! The mRNA Vaccines Working Party of the European Pharmacopeia has taken a significant step forward in ensuring the quality and safety of mRNA-based vaccines. 📝 Draft General Chapters: (1) 5.36 mRNA-LNP Drug Product; (2) 5.39 mRNA Drug Substance; (3) 5.40 DNA Template. These chapters provide comprehensive guidelines for the manufacturing process, characterization, specifications, and analytical control of mRNA vaccines. As the number of clinical trial applications and marketing authorization requests for mRNA-containing products continues to rise, these standards are crucial for maintaining high-quality vaccines. 🗓️ Public Consultation: The draft texts are now available for public consultation until the end of June. 🔗 Read more about this important development on the EDQM website : https://lnkd.in/emqGucNx #mRNAVaccines #QualityStandards #Healthcare #CertestPharma

> Press Release 19 June: WACKER & CordenPharma are pleased to announce their joint consortium has officially entered the pandemic readiness state as of 1 June 2024. Following a successful expansion and qualification phase, the companies are now in stand-by phase for at least five years. In the event of a new pandemic, WACKER and CordenPharma have taken the necessary steps to produce 80 million vaccine doses a year within an extremely short time, with most of the production steps taking place in Germany, and every production step occurring within the European Union. As part of the consortium, CordenPharma is ready to manufacture custom and standard lipids in our Frankfurt (DE) and Chenôve (FR) sites, as well as provide aseptic fill & finish and packaging of the chosen mRNA-based vaccine at our Caponago (IT) facility. In its site in Halle (Germany), WACKER will produce plasmid DNA (pDNA), which is an essential starting material for the manufacture of mRNA. Dr. Michael Quirmbach, CEO of CordenPharma Group, commented: “Obtaining the official confirmation of pandemic readiness by the German government is a major milestone for CordenPharma. I am extremely proud of our teams across the CordenPharma sites involved in establishing and delivering our pandemic readiness plan on schedule. We are now ready, together with our partner WACKER, to manufacture end-to-end mRNA-based vaccines for the German government and other customers.” “We have expanded our Halle site into a Competence Center for mRNA production,” said WACKER CEO Dr. Christian Hartel. “WACKER has invested over 100 million Euros in this expansion and created over 100 highly qualified jobs. Our expertise in making mRNA and LNPs will contribute to the fight against future pandemics. Together with CordenPharma, we are proud to serve the German government in its pandemic preparedness plans.” Read the full press release here: https://lnkd.in/d6vBdaPK #CordenPharma #wacker #pandemic #mrna #pdna #lipids #injectables #fillfinish #pharmaceuticals #vaccine #germany

#News: Sanofi announced a deal worth up to $1.4 billion with Novavax on Friday for its #COVID19vaccine, giving the Maryland-based biotech a much-needed boost to its struggling business. The French pharma is dropping $500 million upfront for #Novavax’s #COVID19 #vaccine, with the goals of co-commercializing its current formulation as well as developing a combination vaccine for #COVID and #flu. An additional $700 million is up for grabs in milestone payments. Along with another potential $200 million in milestones for additional vaccines made with Novavax’s Matrix #adjuvanttechnology, deal totals $1.4 billion—more than double the #biotech’s current market cap of $627 million. Read more from BioSpace 👇🏽 https://lnkd.in/dHCXrgcb

Vaccines are evolving rapidly, and staying updated on the latest trends is crucial for Market Access Professionals. Check out our latest article on the future of vaccines and how upcoming advancements could impact the pharmaceutical landscape. Read more: https://lnkd.in/d-Zr5dvP #Vaccines #HealthcareInnovation #MarketAccess #PharmaceuticalIndustry

Pandemic experience, Surge in innovations and the unmet needs. This McKinsey article gives good insight on Vaccine futuristic path. Gavi, the Vaccine Alliance,African Vaccine Manufacturing Initiative (AVMI), Emerging Biopharmaceutical Manufacturers Network (EBPMN), Developing Countries Vaccine Manufacturers Network (DCVMN International), Vaccines Europe,CEPI (Coalition for Epidemic Preparedness Innovations), PATH

What does the future hold for vaccines? Agilent Technologies will be joining us to discuss the increase in demand for IVT-RNA vaccines. The experts will be discussing their capabilities and possible diseases they could protect against.   This webinar will provide first-hand insights into the best ways to implement quality control measures in IVT-RNA vaccine production.   On the 22nd of January at 10am EST | 3 pm GMT you will get the chance to hear from a panel of experts as they discuss:   📢 The potential use cases for IVT-RNA vaccines 📢How IVT-RNA could bring down the costs of producing vaccines 📢The advantages of IVT-RNA over other forms of biopharma production 📢How to ensure quality control across vaccine manufacturing

📢 More News in Pharma GSK has signed a licensing agreement worth up to €1.4bn with CureVac to develop mRNA vaccines for flu, Covid-19, and avian flu. The deal includes an initial €400mn payment and potential milestone payments of €1.05bn, plus royalties. This agreement will allow GSK to develop combination vaccines for flu and Covid-19, positioning them against competitors like Moderna, Pfizer, and BioNTech SE. CureVac, who are facing commercialisation challenges and a significant drop in shares, will benefit from this cash injection and shift focus to early-stage oncology vaccines, cutting 30% of its workforce to save €25mn annually (𝐢𝐟 𝐲𝐨𝐮 𝐚𝐫𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐞𝐝 𝐛𝐲 𝐭𝐡𝐢𝐬 𝐆𝐄𝐓 𝐈𝐍 𝐓𝐎𝐔𝐂𝐇 𝐖𝐈𝐓𝐇 𝐌𝐄). GSK will fully control vaccine development, enhancing its capabilities against evolving flu and Covid-19 variants. GSK's Chief Scientific Officer, Tony Wood, expressed enthusiasm for the partnership's potential to set new standards in mRNA vaccines. CureVac CEO, Alexander Zehnder, MD, MBA, emphasised the strategic shift to ensure long-term success despite the difficult decision to reduce staff. #Pharma #mRNA #vaccines #biotech #innovation #healthcare #virology #covid

Thoughts on this? >> Meissa Vaccines' future in limbo due to current fundraising climate: CEO >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #healthcare #pharma #biotech